Heron Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $151.2M+4.8% YoYTTM through 30 Jun 2026
Net Income -$34MTTM through 30 Jun 2026
Free Cash Flow -$12.1MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 69.4% |
| EBITDA Margin | -5.8% |
| Operating Margin | -13.8% |
| Net Margin | -22.5% |
Returns
-338.6%ROE
-12.6%ROA
Balance Sheet Health
Debt / Equity15.50x
Current Ratio2.53x
Net Debt$96.8M
Cash & Equivalents$20.7M
Quality Metrics
Altman Z-Score-9.59
Piotroski F-Score2 / 9
FCF Margin-8.0%
Rule of 401.5
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $154.9M
Diluted EPS-$0.19TTMFY2025: $-0.12
Dividend
No dividend
Capital Allocation
R&D Spend$12.3M
Capex Intensity0.3%
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.